Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
The group could soon provide clarity on CTX112’s regulatory path.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
Boehringer discontinues brigimadlin while others continue to struggle.
